Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA-approved for HR+ metastatic breast cancer, from ribociclib and palbociclib.
Related Items


TON Web Exclusives published on February 26, 2018 in Breast Cancer
TON Web Exclusives published on February 26, 2018 in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
Last modified: December 8, 2017